跳至主要内容
临床试验/CTRI/2025/09/095398
CTRI/2025/09/095398尚未招募2 期

A Randomized Clinical Trial to Compare the Efficacy of Phala Ghrita Uttarabasti and Brihat Shatavari Ghrita Uttarabasti on Endometrial receptivity in Unexplained Infertility

National Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年10月15日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
80
试验地点
1
主要终点
Changes in receptivity and expression of alpha v beta 3 integrin in endometrium

研究概览

简要总结

1.   Infertility affects a significant number of couples worldwide, and for about 10-30% of them, the reason remains unknown – a condition called unexplained infertility . One of the key issues in infertility, including unexplained infertility, can be problems with the endometrium, which is the lining of the uterus. For a pregnancy to occur, an embryo needs to successfully attach to a healthy and receptive endometrium. One important factor for this attachment is a protein called alpha V beta 3 integrin, which is found in the uterine lining. Studies have shown that women who have trouble with implantation often have lower levels of this protein. Ayurveda offers various treatments for infertility, and one such method is Uttarabasti. This involves administering medicated oils or ghee directly into the uterus. This study aims to investigate two specific Ayurvedic preparations, Phala Ghrita and Brihat Shatavari Ghrita, administered via Uttarabasti. These preparations have been used in Ayurveda to improve fertility and reproductive health. Currently, there’s limited scientific evidence to explain how these Ayurveda treatments work at a molecular level. This research seeks to bridge that gap by scientifically comparing the effects of Phala Ghrita Uttarabasti and Brihat Shatavari Ghrita Uttarabasti on improving endometrial receptivity and, specifically, the expression of alpha V beta 3 integrin in women with unexplained infertility. The study will involve 80 women (40 in each group) aged 20-40 with unexplained infertility. They will receive either Phala Ghrita or Brihat Shatavari Ghrita via Uttarabasti for six days after their period, for three cycles. Researchers will assess changes in their endometrial receptivity using a scoring system and measure the expression of alpha V beta 3 integrin in their endometrial tissue before and after the treatment. The study will also monitor for any potential side effects. The goal is to see if these Ayurvedic interventions can improve the endometrial receptivity, specifically by enhancing the expression of alpha V beta 3 integrin, and ultimately increase the chances of successful embryo implantation for women with unexplained infertility. If successful, this study could offer a new, holistic treatment option, combining traditional wisdom with modern scientific understanding to help couples struggling to conceive. The study will be conducted over 30 months and will only begin after receiving ethical approval and registration.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
20.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • Married female patients between age group 20 years to 40 years.
  • Patients diagnosed as a case of unexplained infertility with B/l patent fallopian tubes, positive ovulatory status, and normal uterine cavity.
  • Normal semen analysis of partner.

排除标准

  • Women with known cause of infertility.
  • Known case of uro-genital infections, reproductive tract disorders, sexually transmitted diseases and anatomical defect of reproductive/urogenital tract.
  • Known case of medical co morbidity (diabetes mellitus, hypothyroidism) .

结局指标

主要结局

Changes in receptivity and expression of alpha v beta 3 integrin in endometrium

时间窗: 3 menstrual cycle

次要结局

  • safety profile of drugs and Uttarabasti procedure(3 menstrual cycle)

研究者

申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Shweta Raturi

National Institute of Ayurveda

研究点 (1)

Loading locations...

相似试验